Related Experiment Video

Updated: Jun 26, 2025

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.5K

The cutting edge: Promising oncology radiotracers in clinical development

Jorge D Oldan1, Martin G Pomper2, Rudolf A Werner3

  • 1Molecular Imaging and Therapeutics, Department of Radiology, University of North Carolina, Chapel Hill, NC 27516, USA.

Diagnostic and Interventional Imaging
|May 14, 2024
PubMed

Insights

New radiotracers for positron emission tomography (PET) are advancing cancer imaging. These novel agents target the tumor microenvironment, specific cancers like renal cell carcinoma, lymphomas, and immunotherapies, offering improved diagnostic capabilities.

Area of Science:

  • Nuclear medicine
  • Molecular imaging
  • Oncology

Background:

  • Advancements in molecular imaging are driven by new imaging agents.
  • Radiotracers are crucial for nuclear medicine, especially positron emission tomography (PET).
  • New molecular targets are emerging for oncologic applications.

Purpose of the Study:

  • To review major new radiotracers in clinical development for oncologic applications.
  • To discuss the potential advantages of novel agents over current standards like 2-deoxy-2-[18F]fluoro-d-glucose (FDG).
  • To highlight agents targeting the tumor microenvironment, specific cancers, and immunotherapies.

Main Methods:

  • Review of clinical development of new radiotracers.
  • Discussion of agents targeting fibroblast activation protein (FAP).
  • Analysis of carbonic anhydrase IX (CAIX) inhibitors, Pentixafor, adrenergic agents, and immunotherapeutic agents.

Main Results:

  • Fibroblast activation protein (FAP)-targeted agents show potential superiority to FDG in certain tumor types.
  • Carbonic anhydrase IX (CAIX) inhibitors offer new PET imaging for clear cell renal cell carcinoma and hypoxic tumors.
  • Pentixafor enables PET visualization of low-grade lymphomas and multiple myeloma, with theranostic potential.
  • New adrenergic agents provide PET alternatives to meta-[123I]iodobenzylguanidine (MIBG).
  • Novel radiotracers are being developed to assess immunotherapy suitability.

Conclusions:

  • New radiotracers are expanding PET applications in oncology.
  • Targeting the tumor microenvironment and specific cancer biomarkers enhances imaging capabilities.
  • Emerging agents offer improved diagnostics and theranostics for various cancers and treatments.
Keywords:
Carbonic anhydrase IX inhibitorFibroblast activation protein inhibitorImmunotherapyOncologyPentixafor

More Related Videos

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models10:04

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

12.0K
Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method09:08

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

Published on: December 20, 2024

1.3K

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
111
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.2K